Tamer A Ahmed
Overview
Explore the profile of Tamer A Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed T, et al.
Nat Cancer
. 2021 Sep;
2(4):429-443.
PMID: 34568836
CDK4/6 inhibitors (CDK4/6i) are effective in metastatic breast cancer, but they have been only modestly effective in most other tumor types. Here we show that tumors expressing low CDK6 rely...
2.
Adamopoulos C, Ahmed T, Tucker M, Ung P, Xiao M, Karoulia Z, et al.
Cancer Discov
. 2021 Feb;
11(7):1716-1735.
PMID: 33568355
Current clinical RAF inhibitors (RAFi) inhibit monomeric BRAF (mBRAF) but are less potent against dimeric BRAF (dBRAF). RAFi equipotent for mBRAF and dBRAF have been developed but are predicted to...
3.
Ahmed T, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson S, et al.
Cell Rep
. 2019 Jan;
26(1):65-78.e5.
PMID: 30605687
Pharmacologic targeting of components of ERK signaling in ERK-dependent tumors is often limited by adaptive resistance, frequently mediated by feedback-activation of RTK signaling and rebound of ERK activity. Here, we...
4.
Ahmed T, Horn J, Hayslip J, Leggas M
J Pharm Anal
. 2018 Feb;
2(6):403-411.
PMID: 29403775
Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely used in hyperlipidemia therapy. SIM has recently been studied for its anticancer activity at doses higher than those used for...
5.
Karoulia Z, Wu Y, Ahmed T, Xin Q, Bollard J, Krepler C, et al.
Cancer Cell
. 2016 Sep;
30(3):501-503.
PMID: 27622340
No abstract available.
6.
Karoulia Z, Wu Y, Ahmed T, Xin Q, Bollard J, Krepler C, et al.
Cancer Cell
. 2016 Aug;
30(3):485-498.
PMID: 27523909
The complex biochemical effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking. Here we show...
7.
Krepler C, Xiao M, Sproesser K, Brafford P, Shannan B, Beqiri M, et al.
Clin Cancer Res
. 2015 Dec;
22(7):1592-602.
PMID: 26673799
Purpose: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. Experimental Design: We established 12 PDXs from BRAF inhibitor-progressed melanoma patients....
8.
Ahmed T, Hayslip J, Leggas M
Leuk Res
. 2014 Sep;
38(11):1350-7.
PMID: 25262449
Tipifarnib, a farnesyltransferase inhibitor (FTI), was initially designed to disrupt RAS farnesylation and membrane localization necessary for RAS function. However, alternative geranylgeranylation has been postulated as an escape mechanism by...
9.
Ahmed T, Hayslip J, Leggas M
Cancer Chemother Pharmacol
. 2013 Oct;
72(6):1369-74.
PMID: 24162379
Purpose: To evaluate the pharmacokinetics of simvastatin at the maximum tolerated dose (MTD) of 7.5 mg/kg, twice daily, in the context of a pilot trial enrolling patients with recurrent and...
10.
Shaaban K, Shepherd M, Ahmed T, Nybo S, Leggas M, Rohr J
J Antibiot (Tokyo)
. 2012 Oct;
65(12):615-22.
PMID: 23047245
Four new benzamides, pyramidamycins A-D (2-5) along with the new natural 3-hydroxyquinoline-2-carboxamide (6) were isolated from the crude extract of Streptomyces sp. DGC1. Additionally, five other known compounds, namely 2-aminobenzamide...